Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers

Dovilė Pocevičiūtė¹, Cristina Nuñez-Diaz¹, Bodil Roth², Shorena Janelidze¹, The Netherlands Brain Bank³, Andreas Giannisis⁴, Oskar Hansson¹,⁵ and Malin Wennström¹*

Abstract

Background: Alzheimer’s disease (AD) is foremost characterized by β-amyloid (Aβ)-extracellular plaques, tau-intraneuronal fibrillary tangles (NFT), and neuroinflammation, but over the last years it has become evident that peripheral inflammation might also contribute to the disease. AD patients often demonstrate increased levels of circulating proinflammatory mediators and altered antibody levels in the blood. In our study, we investigated the plasma Immunoglobulin A (IgA) levels in association with apolipoprotein E (APOE) ε4 status and Aβ pathology.

Methods: IgA levels in antemortem-collected (cohort I) and postmortem-collected (cohort II) plasma samples from AD patients (n = 30 in cohort I and n = 16 in cohort II) and non-demented age-matched controls (NC) (n = 42 in cohort I and n = 7 in cohort II) were measured using ELISA. Hippocampal sections from cohort II were immunostained against IgA, and the IgA area fraction as well as the number of IgA positive (IgA+) cells in the cornu ammonis region were analysed using ImageJ. The relationship between plasma IgA levels and cognition, C-reactive protein (CRP), and cerebrospinal fluid (CSF) AD biomarkers in cohort I as well as neuropathology, IgA+ cell number, and IgA area fraction in cohort II was analysed before and after grouping the cohorts into APOEε4 carriers and APOEε4 non-carriers.

Results: Plasma IgA levels were higher in AD patients compared to NC in both cohorts. Also, AD patients demonstrated higher IgA area fraction and IgA+ cell number compared to NC. When APOEε4 status was considered, higher plasma IgA levels in AD patients were only seen in APOEε4 non-carriers. Finally, plasma IgA levels, exclusively in APOEε4 non-carriers, were associated with cognition, CRP, and CSF Aβ levels in cohort I as well as with IgA area fraction, IgA+ cell number, and Aβ, Lewy body, and NFT neuropathology in cohort II.

Conclusions: Our study suggests that AD pathology and cognitive decline are associated with increased plasma IgA levels in an APOE allele-dependent manner, where the associations are lost in APOEε4 carriers.

Keywords: Amyloid beta, Blood-brain barrier, Immunoglobulin, Inflammation

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
foremost characterized by the activation of glial cells and increased production of pro-inflammatory mediators, which is reflected in the cerebrospinal fluid (CSF) [3, 4]. Associations between the peripheral inflammation and AD can be found in epidemiological studies demonstrating a decreased risk of AD in individuals using non-steroidal anti-inflammatory drugs [5] and an increased risk of AD in individuals with, for instance, altered gut microbiota [6], long-term exposure to air pollution [7, 8], and oral infections [9]. Several studies also show altered levels of cytokines, such as interleukin (IL)-6 and IL-1, and complements in the blood of AD patients; however, other studies do not confirm these results [10]. To establish the link between AD and peripheral inflammation further, studies have investigated the impact of AD pathology on systemic antibody levels. Antibodies can be found in five different isotypes, from which the most prominent isotypes are immunoglobulin G (IgG), M (IgM), and A (IgA). In the primary immune response, IgM is the first antibody isotype being produced during B cell development [11], whereas in the secondary immune response, mainly IgG is produced and in smaller amounts also IgA. IgG is one of the most abundant proteins in human serum (70 to 160 g/l in serum), being produced in a delayed response to an infection [12, 13]. IgA, on the other hand, is not as abundant (7 to 40 mg/l in serum) and is found in two forms: monomeric in serum and dimeric in the mucosa (i.e. saliva, tears, colostrum, intestinal and genital tract, respiratory secretions) [12, 14]. Previous studies have analysed IgA antibody levels in the blood of AD patients and healthy age-matched controls, but the results are inconsistent with demonstrating either increased [15–18], unaltered [19, 20], or decreased [21] blood IgA levels in AD patients compared to healthy controls. Normally, circulating antibodies are thought to be largely excluded from the immune-privileged central nervous system (CNS) in healthy individuals. However, increased levels of IgA antibodies have been observed in the CSF of many neurological patients, including AD patients [20, 22–26]. Hence, it has been hypothesized that systemically produced antibodies enter the CSF from blood through the breaches in the blood-brain barrier (BBB) that result from pathological processes such as neuroinflammation [27]. For instance, Goldwaser et al. reported that IgA autoantibodies cross the BBB, bind to neuronal surface molecules, and enhance Aβ42 penetration and deposition into neuronal cells, possibly leading to subsequent neuronal dysfunction and loss of synapses [28]. Whether other antibody isotypes, such as IgA or IgM, also cross the BBB and bind to brain cells is less clear. An increasing number of studies report that the inflammatory response in the periphery is also associated with apolipoprotein E (APOE) gene [29–31], the main genetic determinant for late-onset AD. The APOE is produced in several organs (i.e. liver, adrenal gland, brain) and by various cell types (i.e. ovarian and adrenal cells, macrophages, astrocytes, oligodendrocytes, pericytes, choroid plexus cells, neurons) and is associated with lipid transport and cholesterol homeostasis [32]. There are three alleles of the APOE gene: APOEε2, APOEε3, and APOEε4, from which the latter increases the risk of AD by 3–4 times in heterozygotes and by 12–15 times in homozygotes compared with APOEε3 carriers [33]. The role of APOEε4 in AD is mostly established in the CNS, where it is known to affect Aβ aggregation and clearance, as well as influence neuroinflammation, BBB permeability, synaptic plasticity, and tau hyperphosphorylation [34]. However, recent findings suggest a direct link between liver-derived APOEε4 and pathological changes in the mouse brain [35]. Additionally, given its suggested immune-modulatory effect [29–31], it may be that APOEε4 contributes to AD pathology via its impact on the peripheral immune response. Such impact might explain the inconsistency in plasma IgA levels reported by other groups [15–21] as APOE polymorphism was not considered in previously published studies. Hence, we found it interesting to investigate the IgA levels in AD patients in general and when the APOE polymorphism is accounted for. We therefore analysed the plasma IgA levels in two cohorts consisting of AD patients and non-demented controls (NC), where the plasma was collected antemortem (cohort I) and postmortem (cohort II). To further analyse the potential effect of APOEε4 on IgA levels in relation to AD pathology, we divided the cohorts based on APOEε4 status and investigated the differences between clinical diagnoses as well as associations between plasma IgA levels and cognition, CRP, and CSF AD biomarkers in cohort I and neuropathology and brain IgA immunoreactivity in cohort II.

**Methods**

**Individuals included in the study**

The study was performed on antemortem collected plasma samples from (n = 72) individuals (cohort I) and postmortem collected plasma and brain samples from (n = 23) individuals (cohort II). Cohort I consisted of NC (n = 42) and AD (n = 30) patients examined at the Memory Clinic at Skåne University Hospital, Sweden. Both controls and AD patients underwent cognitive and neurological assessments by a physician with a special interest in dementia disorders. Patients with AD were diagnosed according to the DSM-IV Criteria for Alzheimer’s disease. The cognitively healthy individuals displayed no neurological or cognitive deficiency symptoms. None of the study participants from cohort I had a systemic illness or was using anti-inflammatory medications. The
NC and AD patients have been included in a previous study, and thus, the demographic data, scores of cognitive tests, APOEε4 status, and levels of CSF AD biomarkers, Q-Albumin, and C-reactive protein (CRP) have been published previously [36]. The cognitive tests include the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog), A Quick Test (AQT), and Mini-Mental State Examination (MMSE). The CSF AD biomarkers Aβ40, Aβ42, phosphorylated tau (p-tau), and total tau (t-tau) were analysed using Euroimmun ELISA (Euroimmun AG), and albumin levels in plasma and CSF samples were measured by immunoturbidimetry on a Roche Cobas Analyzer (Roche Diagnostics). The Q-Albumin was calculated as CSF albumin (mg/l)/plasma albumin (g/l) ratio and was used as a measure of the BBB function. The mean values of the variables can be found in Table 1.

Cohort II consisted of donors from The Netherlands Brain Bank (NBB) and included NC (n = 7) and clinically verified AD patients (n = 16). The presence of Aβ plaques was scored into O, A, B, and C according to Braak [37], where O = zero, A = some, B = moderate, and C = many, and the presence of NFT and neuropil threads was scored according to Braak stages I–VI [37]. Demographic data of the NC and AD groups is shown in Table 2, and demographic data, neuropathological evaluation, and cause of death of each case are found in Supplementary Table 1. Five individuals (n = 1 NC and n = 4 AD patients) were treated with anti-inflammatory medications during their last 3 months prior to death, and none of the individuals used anti-inflammatory medications during the last 24 h. The informed consent for the use of plasma samples, brain sections, and/or clinical data for research purposes was obtained from all patients included in cohorts I and II or their next of kin. The study was approved by the ethics committee in Lund, Sweden, and all investigations were conducted in agreement with the Declaration of Helsinki [38]. The procedures for brain tissue collection were approved by the Medical Ethics Review Committee of VU Medical Centre in Amsterdam (The Netherlands).

### Table 1 Clinical data of individuals included in cohort I

|                     | NC, n = 42 | AD, n = 30 |
|---------------------|------------|------------|
| Age (years)         | 74 ± 6     | 74 ± 7a    |
| Females (%)         | 69         | 70         |
| APOEε4 carriers (%) | 38         | 70         |
| ADAS-Cog (score)    | 1.88 ± 1.70| 8.67 ± 1.90ab   |
| AQT (score)         | 63.24 ± 10.36| 110.18 ± 46.72a  |
| MMSE (score)        | 29.19 ± 0.83| 19.50 ± 4.27a  |
| CRP (mg/l)          | 1.75 ± 1.59| 6.94 ± 13.12a  |
| CSF Aβ40 (pg/ml)    | 6759.52 ± 1906.93| 6452.66 ± 1675.20a |
| CSF Aβ42 (pg/ml)    | 791.67 ± 289.29| 386.70 ± 110.29a |
| CSF p-tau (pg/ml)   | 45.61 ± 18.16| 120.40 ± 41.24a |
| CSF t-tau (pg/ml)   | 341.53 ± 106.23| 621.81 ± 207.42a |
| Q-albumin           | 6.75 ± 3.80| 6.80 ± 2.54a |

Aβ amyloid beta, AD Alzheimer’s disease, ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive Subscale, APOE4 apolipoprotein 4, AQT A Quick Test, CRP C-reactive protein, CSF cerebrospinal fluid, MMSE Mini-Mental State Examination, NC non-demented control, p-tau phosphorylated tau, t-tau total tau

* Data were analysed using either Student’s t-test or Mann-Whitney U-test, and values are presented as mean value ± SD
*Significant at p ≤ 0.05 level
**Significant at p ≤ 0.01 level
***Significant at p ≤ 0.001 level

### Table 2 Clinical data of individuals included in cohort II

|                     | NC, n = 7 | AD, n = 16 |
|---------------------|------------|------------|
| Age (years)         | 78 ± 9     | 80 ± 11a   |
| Females (%)         | 57         | 56         |
| APOEε4 carriers (%) | 14         | 69         |
| PMD (h)             | 6.11 ± 1.30| 6.06 ± 1.25a |

AD Alzheimer’s disease, APOE4 apolipoprotein 4, NC non-demented control, PMD postmortem delay

* Data were analysed using Student’s t-test, and values are presented as mean value ± SD
*Significant at p ≤ 0.05 level
**Significant at p ≤ 0.01 level
***Significant at p ≤ 0.001 level

### Stratification of cohorts

Individuals from both cohorts were stratified into the following groups: NC, AD, APOEε4 non-carriers, and APOEε4 carriers. Individuals with genotypes APOEε23 (n = 4 in cohort I and n = 2 in cohort II) and APOEε33 (n = 31 in cohort I and n = 9 in cohort II) were stratified as APOEε4 non-carriers. Individuals with APOEε24 (n = 2 in cohort I) as well as APOEε34 (n = 29 in cohort I and n = 9 in cohort II) and APOEε44 (n = 6 in cohort I and n = 3 in cohort II) were stratified as APOEε4 carriers.

### Immunohistochemistry

The hippocampi of all individuals included in cohort II were stained against IgA using immunohistochemistry according to the following protocol: immersion paraformaldehyde (PFA)-fixed brain samples were sectioned into 40-μm sections using a microtome and kept free-floating in antifreeze medium in −20°C. For immunostainings, the sections were rinsed three times with phosphate-buffered saline containing potassium (KPBS) and quenched for 30 min at room temperature (RT) with a quenching solution (10% peroxidase, 10% methanol, and 80% KPBS). Then, brain sections were rinsed three more times with KPBS. Next, the blocking solution
Finally, the brain sections were mounted with 95% EtOH, 10 min in 99% EtOH, and 10 min in xylene. 3,3′-diaminobenzidine (DAB) diluted 1:50 in KPBS, and the samples were left to incubate for 2 min. Then, the DAB was removed, and the samples were washed three times with KPBS+ and two times with KPBS. Then, in the flow hood, KPBS was replaced with 3,3′-diaminobenzidine (DAB) diluted 1:10 in KPBS, and the samples were left to incubate for 10 min. Following the incubation, hydrogen peroxide (H$_2$O$_2$) diluted 1:10 in KPBS was added to the samples with DAB, and the samples were left to incubate for 2 min. Then, the DAB and H$_2$O$_2$ were removed, and the samples were washed 3 times with KPBS. Later, the brain sections were placed on glass slides, dried, and dehydrated in the following order: 5 min in ddH$_2$O, 5 min in 70% ethanol (EtOH), 10 min in 95% EtOH, 10 min in 99% EtOH, and 10 min in xylene. Finally, the brain sections were mounted with mounting medium (DPX) and coverslipped. Analysis of the IgA immuno-stained area fraction in cohort II was performed by selecting the same three areas in three sections (in total 9 images) from each individual. The images were analysed using the Fiji software (ImageJ) by applying an automated threshold. The values were averaged and presented as mean optical density (OD) area fraction (%). To investigate the distribution of IgA-positive (IgA+) cells between the analysed groups, IgA+ cells were counted with ImageJ blinded to the observer and the average number of IgA+ cells per section was calculated.

**Analysis of plasma IgA**

The plasma IgA levels were measured using a commercially available Human IgA ELISA kit (Mabtech, Nacka Strand, Sweden) according to the manufacturer’s instructions. Shortly, randomized samples blinded to the experimenter were diluted 1:50000 in incubation buffer and applied (in duplicates) to optically clear 96-well flat bottom microplates (Nunc, Thermo Scientific), coated with capture mAb MT57 diluted to 2 μg/ml in PBS. Then, detection mAb MT20-ALP diluted 1:1000 in incubation buffer was applied. Finally, the plates were incubated with pNPP substrate, and the optical density was measured in an ELISA reader at a wavelength range of 405–650 nm (BioTek).

**APOE genotyping**

APOE genotype in cohort II was determined by real-time polymerase chain reaction (PCR) using TaqMan® Universal PCR Master Mix No AmpErase® UNG (Applied Biosystems) and TaqMan® single nucleotide polymorphisms genotyping assays (Thermo Scientific) targeting the rs429358 and rs7412 variants of the APOE gene. Amplification was performed using the QuantStudio™ 5 Real-Time PCR System, 384-well (Applied Biosystems), and the results were analysed using the Thermo Fisher Cloud software. Prior to genotype assessment, DNA was extracted from brain samples using the QIAGEN DNeasy Blood & Tissue Kit according to the supplier’s guidelines. Following extraction, DNA concentration and quality were assessed using NanoDrop™ One/OneC Microvolume UV-Vis Spectrophotometer (Thermo Scientific).

**Statistical analyses**

All statistical analyses were performed using the SPSS software (version 28.0.0.0). The Kolmogorov-Smirnov test was used to assess normal distribution. Normally distributed samples (age, CSF Aβ40 levels, and plasma IgA levels in cohort I and age, postmortem delay, NFT scores, and plasma IgA levels in cohort II) were analysed using Student’s t-test. Non-normally distributed samples (ADAS-Cog scores, AQT scores, MMSE scores, CRP levels, CSF Aβ42 levels, CSF p-tau levels, CSF t-tau levels, and Q-albumin in cohort I and Aβ plaque scores, LB scores, CA1 IgA+ cell number, and CA1 IgA area fraction in cohort II) were analysed using the Mann-Whitney U-test. Correlations between the investigated variables in both cohorts were performed using the 2-tailed Spearman’s correlation test. Correlations and differences were considered significant at $p \leq 0.05$.

**Results**

**Plasma IgA levels are higher in AD patients**

**Cohort I**

Analysis of plasma IgA levels showed that AD patients in cohort I had significantly higher IgA levels compared to NC (Fig. 1A). No significant differences in IgA levels were seen between males and females ($4.14 \pm 1.78$ vs $3.60 \pm 1.49$ mg/ml, respectively) ($p = 0.186$).

**Cohort II**

In cohort II, plasma IgA levels were also significantly higher in AD patients compared to NC (Fig. 1B). As in
In cohort I, there was no significant difference in IgA levels between males and females (73.93 ± 51.45 vs 75.06 ± 50.82 mg/ml, respectively) (p = 0.959).

**Plasma IgA levels are higher in APOEε4 negative AD patients**

**Cohort I**

Next, we analysed plasma IgA levels in APOEε4 carriers and APOEε4 non-carriers. In cohort I, the IgA levels did not differ between APOEε4 carriers and non-carriers (3.72 ± 1.45 vs 3.81 ± 1.75 mg/ml, respectively) (p = 0.809). However, after the cohort was stratified into APOEε4 carriers and non-carriers and the IgA levels were compared between NC and AD patients, the levels were significantly higher in AD patients compared to NC exclusively in APOEε4 non-carriers (Fig. 1C). In contrast, there was no significant difference in IgA levels between APOEε4-carrying AD patients and NC (p = 0.637) (Fig. 1D). Furthermore, IgA levels in NC did not differ between APOEε4 non-carriers and carriers (3.36 ± 1.72 vs 3.59 ± 1.38 mg/ml, respectively) (p = 0.652), but IgA levels in AD patients were significantly higher in APOEε4 non-carriers compared to carriers (Additional file 2: Fig. S1).

**Cohort II**

In cohort II, there was also no significant difference in plasma IgA levels between APOEε4 carriers and APOEε4 non-carriers (75.64 ± 44.07 vs 73.39 ± 57.82 mg/ml, respectively) (p = 0.917). However, after the cohort was stratified into APOEε4 carriers and non-carriers, the levels were significantly higher in AD patients compared to NC in APOEε4 non-carriers (Fig. 1E). Of note, APOEε4 carriers could not be analysed due to the low number of NC (n = 1) in this group. Furthermore, we noted higher, albeit not significantly, IgA levels in APOEε4 non-carrying AD patients compared to APOEε4-carrying AD patients (120.26 ± 45.69 vs 75.43 ± 46.21 mg/ml, respectively) (p = 0.093).

**Hippocampal IgA area fraction is higher in AD patients**

The IgA area fraction in the hippocampal CA1 region was significantly higher in AD patients compared to NC (Fig. 2C). In contrast, the IgA area fraction did not differ between APOEε4 non-carriers and carriers (8.03 ± 22.54 vs 7.54 ± 15.24, respectively) (p = 0.151). The IgA immunostaining yielded staining of vessels (Fig. 2A) and structures resembling neurons and glial cells (Fig. 2B). We found significantly more IgA+ cells in AD patients compared to NC (Fig. 2D). As in the case with IgA area fraction, there was no significant difference in the number of IgA+ cells between APOEε4 carriers and non-carriers (30.75 ± 42.14 vs 13.74 ± 29.78, respectively) (p = 0.365). Based on the diagnosis, 29% of NC and 93% of AD patients had IgA+ cells. In the case of the APOEε4 status, 64% of the APOEε4 non-carriers and 82% of the carriers had IgA+ cells.

**Plasma IgA levels correlate with cognition, CRP, CSF AD biomarkers, neuropathology, and brain immunoreactivity**

**Cohort I**

Finally, we performed correlation analyses in both cohorts. In cohort I, we analysed the correlation
between the plasma IgA levels and cognition (assessed by ADAS-Cog, MMSE, and AQT memory tests), inflammation (indicated by CRP levels), BBB permeability (indicated by Q-albumin ratio), and CSF AD biomarkers such as CSF Aβ40, Aβ42, p-tau, and t-tau. When the whole cohort was analysed, IgA levels correlated with CSF Aβ40, CSF Aβ42, and CSF Aβ42/40 ratio (Table 3). When the cohort was stratified into NC and AD patients, IgA levels correlated with CSF Aβ42 only in NC (Table 3). When the cohort was stratified into APOEε4 carriers and APOEε4 non-carriers, the IgA levels correlated with MMSE, AQT, CRP, CSF Aβ40, CSF Aβ42, and CSF Aβ42/40 ratio only in APOEε4 non-carriers (Table 3). Plasma IgA levels did not correlate with age in NC ($r = -0.086$, $p = 0.588$).

**Cohort II**

In cohort II, we analysed the potential correlations between the plasma IgA levels and neuropathological features including Aβ plaques, Lewy bodies (LB), and NFT, as well as the IgA area fraction and IgA+ cell number in the hippocampal CA1 region. When the whole cohort was analysed, IgA levels correlated with IgA+ cell number and IgA area fraction (Table 4). When the cohort was divided upon diagnosis, IgA levels correlated with IgA area fraction only in AD patients (Table 4). When the cohort was stratified into APOEε4 non-carriers and APOEε4 carriers, IgA levels correlated with IgA+ cell number as well as Aβ, LB, and NFT neuropathology only in APOEε4 non-carriers (Table 4). The IgA area fraction, on the other hand, correlated with IgA levels in both

---

**Table 3** Correlations between the plasma IgA levels and cognition, CRP, and CSF AD biomarkers in cohort I

| Variables      | All groups | NC | AD | −APOEε4 | +APOEε4 |
|----------------|------------|----|----|---------|---------|
| MMSE (score)   | ns         | ns | ns | −0.499**| ns      |
| AQT (score)    | ns         | ns | ns | 0.438*  | ns      |
| CRP (mg/l)     | ns         | ns | ns | 0.534** | ns      |
| CSF Aβ40 (pg/ml) | −0.246*  | ns | ns | −0.390* | ns      |
| CSF Aβ42 (pg/ml) | −0.349** | −0.393* | ns | −0.582*** | ns      |
| CSF Aβ42/40   | −0.268*    | ns | ns | −0.472** | ns      |

Data were analysed using Spearman’s correlation test

Aβ amyloid beta, AD Alzheimer’s disease, APOE4 apolipoprotein 4, −APOE4 APOE4 non-carrier, +APOE4 APOE4 carrier, AQT A Quick Test, CRP C-reactive protein, CSF cerebrospinal fluid, MMSE Mini-Mental State Examination, NC non-demented control, ns not significant

*Significant correlation at $p \leq 0.05$ level

**Significant correlation at $p \leq 0.01$ level

***Significant correlation at $p \leq 0.001$ level

---

**Table 4** Correlations between the plasma IgA levels and neuropathology as well as hippocampal IgA area fraction and IgA-positive cell number in cohort II

| Variables      | All groups | NC | AD | −APOEε4 | +APOEε4 |
|----------------|------------|----|----|---------|---------|
| Aβ (score)     | ns         | ns | ns | 0.741** | ns      |
| LB (score)     | ns         | ns | ns | 0.702*  | ns      |
| NFT (score)    | ns         | ns | ns | 0.840***| ns      |
| IgA+ cells (no.) | 0.560**  | ns | ns | 0.893***| ns      |
| IgA area fraction (%) | 0.688*** | ns | 0.564* | 0.918***| 0.618*  |

Data were analysed using Spearman’s correlation test

Aβ amyloid beta, AD Alzheimer’s disease, APOE4 apolipoprotein 4, −APOE4 APOE4 non-carrier, +APOE4 APOE4 carrier, AQT A Quick Test, CRP C-reactive protein, CSF cerebrospinal fluid, MMSE Mini-Mental State Examination, NC non-demented control, NFT neurofibrillary tangle, no. number, ns not significant

*Significant correlation at $p \leq 0.05$ level

**Significant correlation at $p \leq 0.01$ level

***Significant correlation at $p \leq 0.001$ level
APOEε4 non-carriers and carriers (Table 4). Plasma IgA levels did not correlate with age or postmortem delay in NC ($r = 0.450$, $p = 0.310$; $r = −0.432$, $p = 0.333$, respectively).

Subsequently, we analysed whether the IgA area fraction and the number of IgA+ cells in hippocampal CA1 correlate with Aβ plaques, LB, and NFT. When we analysed all groups, IgA area fraction correlated with Aβ score and IgA+ cell number correlated with both Aβ and NFT scores (Table 5). When we divided the cohort upon diagnosis, IgA+ cell number correlated with LB score only in NC (Table 5). Finally, when we looked at APOEε4 non-carriers and APOEε4 carriers, both IgA area fraction and IgA+ cell number correlated with Aβ, LB, and NFT scores exclusively in APOEε4 non-carriers (Table 5).

**Discussion**

In the current study, we found increased levels of plasma IgA in AD patients, which was exclusively seen in APOEε4 non-carriers. In addition, plasma IgA levels were associated with cognitive decline, CRP, Aβ pathology, and brain IgA immunoreactivity in APOEε4 non-carriers. These associations were lost in APOEε4 carriers.

The increase in plasma IgA levels in AD patients fits well with previous studies demonstrating higher blood IgA levels in AD patients [16–18] or patients with cognitive dysfunctions [15], but contradicts other studies showing unaltered [19, 20] or decreased [21] blood IgA levels in AD patients. However, it should be noted that none of the previous studies has accounted for APOEε4 status. We show that the AD-related increase in plasma IgA levels is foremost attributed to APOEε4 non-carriers. Thus, it may be that the inconsistency in the results of previous reports on blood IgA levels in AD patients is due to the varied inclusion of APOEε4 carriers in analysed cohorts. The increase in plasma IgA levels in AD patients is interesting from the perspective that IgA is the most prominent Ig isotype found on mucosal surfaces, such as saliva, tears, colostrum, intestinal and genital tract, and respiratory secretions. In fact, globally, there is more IgA produced than all other isotypes combined [14, 39]. Thus, it is tempting to speculate that the increase in plasma IgA levels in AD patients is related to the inflammatory events in the mucosa previously reported to be associated with AD [40, 41]. However, the majority of IgA in the serum is monomeric (which is produced in the bone marrow), and only 1.6–7.1% of the total serum IgA is dimeric IgA deriving from the mucosa [14, 42]. Thus, we find it unlikely that the increase in plasma IgA levels in AD patients is due to a mucosa-related inflammation, but further studies are highly warranted.

Not only plasma IgA levels were higher in AD patients, but also a higher brain IgA area fraction and IgA+ cell number were detected in these individuals. The IgA immunostaining in NC was foremost seen in the vessels, while in AD patients, it was often found in the brain parenchyma where it was visualized as structures resembling neurons and glial cells. Other studies have demonstrated a significant increase in vessel-associated Igs in the parenchyma of AD brains compared to NC brain tissue. In addition, Ig-positive (Ig+) staining extended throughout the neuronal cell bodies, which showed apoptotic features that were not observed in Ig-negative neurons [43]. Another study performed on brain-reactive serum antibodies reported a significantly greater percentage of Ig+ neurons in the brain regions (including the hippocampus) of healthy human brains incubated with the serum of AD patients compared to the serum of NC. The authors indicated that neuron-binding antibodies are abundant in the serum of AD patients and that they could be either the cause or the result of cerebral lesions routinely found in AD brains [44]. The findings were supported by other research groups, as

| Table 5 | Correlations between the hippocampal IgA area fraction and IgA-positive cell number and neuropathology in cohort II |
|----------------------|-------------------------------------------------|-----------------|----------------|-----------------|-----------------|
| **Neuropathology (score)** | **All groups** | **NC** | **AD** | **−APOEε4** | **+APOEε4** |
| IgA area fraction (%) | Aβ | $0.489^*$ | ns | ns | $0.836^{***}$ | ns |
| | LB | ns | ns | ns | $0.735^*$ | ns |
| | NFT | ns | ns | ns | $0.855^{***}$ | ns |
| IgA+ cells (no.) | Aβ | $0.502^*$ | ns | ns | $0.862^{***}$ | ns |
| | LB | ns | $0.820^*$ | ns | $0.660^*$ | ns |
| | NFT | $0.506^*$ | ns | ns | $0.844^{***}$ | ns |

Data were analysed using Spearman’s correlation test

Aβ amyloid beta, AD Alzheimer’s disease, APOE4 apolipoprotein 4, −APOEε4 APOEε4 non-carrier, +APOEε4 APOEε4 carrier, IgA immunoglobulin A, IgA+ immunoglobulin A-positive, LB Lewy body, NC non-demented control, NFT neurofibrillary tangle, no. number, ns not significant

*Significant correlation at $p \leq 0.05$ level

**Significant correlation at $p \leq 0.01$ level

***Significant correlation at $p \leq 0.001$ level
they demonstrated that circulating IgG autoantibodies bind to dying neurons in the vicinity of the cortical lesions in the brains of adult rats, possibly to participate in the phagocytosis and removal of injured neurons [45]. The mentioned studies, including our own, point out that AD pathology is associated with a higher frequency of circulating Ig binding to parenchyma and especially to neuronal and glial cells. The literature on human brain IgA immunoreactivity is rather scarce, but studies have demonstrated IgA+ neurons and glial cells in children aged 3 to 7 months [46] and IgA deposition in the brain of a patient with gluten ataxia [47]. The underlying cause of the increase of IgA area fraction in the brain parenchyma of AD patients in our study warrants further investigation, but a probable scenario is that the BBB permeability is enhanced in these patients. In our study, we found no correlation between plasma IgA levels and Q-albumin ratio, and the Q-albumin ratio did not differ between NC and AD patients in cohort I. However, previous studies have demonstrated an increased Ig immunoreactivity and the presence of Ig+ neurons and glial cells in postmortem AD brains in association with BBB [43, 48–50]. Whether inflammatory events in the periphery, reflected by the increase in plasma IgA levels, induce the BBB permeability or if the AD-related neuroinflammatory events in the brain cause BBB leakage is still under debate. The former idea is supported by studies demonstrating that proinflammatory mediators from the blood can enter the CNS via neural or humoral pathways promoting a proinflammatory environment in the brain and subsequently inducing molecular changes that exacerbate neurodegeneration [51]. For instance, in the animal model of AD, peripheral administration of lipopolysaccharide increased BBB permeability, brain IL-6 levels, and sickness behaviour in amyloid precursor protein (APP)-transgenic mice, suggesting that peripheral inflammation might spread to the brain through permeable BBB and affect the severity of behavioural problems in AD APP-transgenic mice [52]. In view of this finding, it is interesting that we documented a positive correlation between plasma IgA levels and hippocampal CA1 IgA area fraction in AD patients, as it suggests that peripheral IgA-mediated inflammatory processes are associated with an enhanced influx of IgA through the BBB. In addition, plasma IgA levels correlated negatively with CSF Aβ (indicative of increased brain Aβ load) in cohort I and positively with Aβ plaques in cohort II, suggesting that brain Aβ accumulation is associated with the elevation of IgA levels in the blood and brain. This idea fits well with the previous study, demonstrating that peripheral intravenous IgG penetrates through the BBB and enhances microglia-mediated clearance of Aβ [53].

The plasma IgA levels did not differ significantly between APOEε4 carriers and APOEε4 non-carriers in either of the analysed cohorts. This was, however, only evident when the NC in the two APOEε4 groups were compared, which indicates that under normal non-pathological conditions IgA production is not affected by the APOEε4. This finding is in line with studies demonstrating no significant difference in either blood IgA levels [54] or plasma IgG levels [55] between APOEε4 and APOEε3 mice. However, when we compared AD patients based on APOEε4 status, plasma IgA levels were significantly higher in APOEε4 non-carriers compared to APOEε4 carriers. Hence, it seems like the normal IgA response to AD-related inflammatory events (as hypothesized) is disturbed in APOEε4 carriers. Such APOEε4-dependent disturbance of IgA response linked to AD has not (to our knowledge) been reported before.

The idea that the normal IgA response is disturbed in APOEε4 carriers was further highlighted by the found correlations after analysis of cohort I. Here, plasma IgA levels correlated significantly with CRP, Aβ pathology, and cognitive decline exclusively in APOEε4 non-carriers. The lost association between CRP and IgA in APOEε4 carriers again supports the idea that APOEε4 affects the relationship between IgA levels and inflammatory processes, while the association between CSF Aβ and IgA levels in APOEε4 non-carriers supports a role for IgA in AD pathology. The cognitive decline was assessed by three memory tests, MMSE (a 30-point test, where lower scores indicate more severe cognitive impairment), AQT (a test of cognitive speed, where higher scores correspond to a slower perception speed to visual stimuli and a lower rate of correct answering), and ADAS-Cog (cognition rating scale, where higher scores indicate greater cognitive and non-cognitive dysfunction). Since plasma IgA levels correlated negatively with MMSE and positively with AQT in APOEε4 non-carriers, it suggests that plasma IgA levels are associated with impaired cognition in these individuals. This finding, to our knowledge, has not been reported before. However, a recent study demonstrated a cognitive decline in patients with high levels of IgA anti-N-methyl-D-aspartate receptor autoantibodies [56], which fits well with our results.

Finally, it is important to point out that our study has limitations. Firstly, the sample size of both cohorts is small, in particular cohort II, which could contribute to statistical error type 1. Follow-up studies, larger cohorts (preferably with more APOEε4 carriers in the postmortem NC group), are thus warranted to verify our result. We would however like to point out that although the sample sizes are small, we found similar results in both cohorts (i.e. increased levels of IgA in AD patients and associations between AD pathology and IgA exclusively in APOEε4 non-carriers). Secondly, cohort II contained five cases (n = 1 NC and n = 4 AD patients) who were
treated with anti-inflammatory medications during their last 3 months prior to death. The plasma IgA levels of the four AD cases did not differ from AD cases without anti-inflammatory treatment (data not shown), suggesting a minor impact of the medications in these cases. Nevertheless, we cannot entirely exclude the possibility that the anti-inflammatory medications (or the condition they are prescribed for) can affect the results.

To conclude, our study demonstrating an association between plasma IgA levels and cognitive decline as well as AD pathology supports the idea that peripheral inflammation is implicated in AD. However, this event appears to be strongly affected by APOEε4, where the increase in plasma IgA levels and correlation with cognitive decline and AD pathology is lost in APOEε4 carriers. These findings support the previously shown role for APOEε4 in AD pathogenesis and highlight the heterogeneity of the disease, where polymorphic genetic factors modulating inflammatory responses might be of importance. The study further suggests that APOEε4 should be accounted for when measuring plasma IgA levels, in particular in AD patients, which limits a potential application in clinical routine. Future studies investigating the impact of APOEε4 on IgA production and regulation are warranted as they might shed light on mechanisms implicated in the increased risk for AD in APOEε4 carriers.

**Abbreviations**

AD: Alzheimer’s disease; ADAS-Cog: Alzheimer’s Disease Assessment Scale-Cognitive Subscale; APOE: Apolipoprotein E; APP: Amyloid precursor protein; AQF: A Quick Test; AB: Amyloid beta; BBB: Blood-brain barrier; CA1: Cornu ammonis; CRP: C-reactive protein; CSF: Cerebrospinal fluid; IgA: Immunoglobulin A; LB: Lewy body; MMSE: Mini-Mental State Examination; NC: Non-demented control; NFT: Neurofibrillary tangle; p-tau: Phosphorylated tau; PMD: Postmortem delay; t-tau: Total tau.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13195-022-01062-z.

**Acknowledgements**

The authors kindly thank all participants for their contributions.

**Authors’ contributions**

DP and MW contributed to the study concept and design. DP performed the Ig analysis and analysed the data. SJ performed the AD biomarker analysis. AG performed the APOE genotyping. NBB performed the sample collection and neuropathological evaluation. BR, CND, and OH revised the manuscript for intellectual content. All authors approved the final manuscript.

**Funding**

Open access funding provided by Lund University. MW is supported by the Swedish Research Council (2018-02564), the Swedish Brain Foundation (FO2021-0176), the Crabfofd foundation (20210507), the Åhléns foundation (213007), the Dementia Foundation, and Gamla Tjänarinnor. The funding sources had no role in the design and conduct of the study; in the collection, analysis and interpretation of the data; or in the preparation, review or approval of the manuscript.

**Availability of data and materials**

The data sets supporting the conclusions of this article can be made available upon request. MDCS data can be requested through an application to the MDCS steering committee.

**Declarations**

**Ethics approval and consent to participate**

All participants gave written informed consent to participate in the study. Ethical approval was given by the regional ethics committee at Lund University, Sweden.

**Consent for publication**

Not applicable.

**Competing interests**

CH has acquired research support (for the institution) from ADx, AVID Pharmaceuticals, Biogen, Eli Lílly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amrylx, Alzpath, BiArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche, and Siemens.

**Author details**

1. Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden. 2. Department of Internal Medicine, Lund University, Skåne University Hospital, Malmö, Sweden. 3. Netherlands Institute for Neuroscience, Meibergdreef 47, 1105, BA, Amsterdam, The Netherlands. 4. Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden. 5. Memory Clinic, Skåne University Hospital, Malmö, Sweden.

**Received:** 3 June 2022  **Accepted:** 15 August 2022  **Published online:** 26 August 2022

**References**

1. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Winiewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci. 1986;83(13):4913.
2. Masters CL, Multhup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer’s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985;4(11):2757–63.
3. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer’s disease. PLoS One. 2012;7(11):e030525.
4. Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, et al. The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer’s but not Parkinson’s disease or dementia with Lewy bodies. PLoS One. 2015;10(8):e0135458.
5. Zhang C, Wang Y, Wang D, Zhang J, Zhang F. NSAIAD exposure and risk of Alzheimer’s disease: an updated meta-analysis from cohort studies. Front Aging Neurosci. 2018;10:83.
6. Cattaneo A, Cattane N, Galluzzo S, Provasi S, Lopizzo N, Festari C, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging. 2017;49:60–8.
7. Carey IM, Anderson HR, Atkinson RW, Beevers SD, Cook DG, Strachan DP, et al. Are noise and air pollution related to the incidence of dementia? A cohort study in London, England. BMJ Open. 2018;8(9):e022404.
55. Zhang L, Xu J, Gao J, Chen P, Yin M, Zhao W. Decreased immunoglobulin G in brain regions of elder female APOE4-TR mice accompany with Aβ accumulation. Immun Ageing. 2019;16(1):2.
56. Bartels F, Strönisch T, Farmer K, Rentzsch K, Kiecker F, Finke C. Neuronal autoantibodies associated with cognitive impairment in melanoma patients. Ann Oncol. 2019;30(5):823–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.